Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 6Urinary Bladder Neoplasms 3Stomach Neoplasms 3Ovarian Neoplasms 2Carcinoma, Transitional Cell 2Triple Negative Breast Neoplasms 1Rectal Neoplasms 1Neoplasms 1Muscle Invasive Bladder Cancer (MIBC) 1Head and Neck Neoplasms 1HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma 1HER2-low Breast Cancer 1Gastric Adenocarcinoma 1Endometrial Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Biliary Tract Neoplasms 1Advanced Breast Cancer 1

Interventions

Capecitabine 41Oxaliplatin 39Fluorouracil 29Leucovorin 23Radiotherapy 21Cetuximab 14Bevacizumab 14Irinotecan 13Nivolumab 12Magnetic Resonance Spectroscopy 11Specimen Handling 9Surgical Procedures, Operative 8Folfox protocol 8Drug Therapy 8pembrolizumab 7Radiotherapy, Intensity-Modulated 7Chemoradiotherapy 7Biopsy 7trifluridine tipiracil drug combination 6Radiation 6tislelizumab 5sintilimab 5regorafenib 5dehydroftorafur 5X-Rays 5Surveys and Questionnaires 5Sigmoidoscopy 5Endoscopy 5Consolidation Chemotherapy 5spartalizumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Rectal Neoplasms × disitamab vedotin × 1 year × Clear all
NCT07509424 2026-04-03

Neoadjuvant Short-course Radiotherapy Followed by a Combination of Disitamab Vedotin, Sintilimab, and Capecitabine in Locally Advanced HER2-expressing Rectal Cance

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Phase 2 Not yet recruiting
29 enrolled
Gastrointestinal

Rectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡